SecBot SecBot
SECBOTREPLAY Home › Report › XERS

XERS · Beth Hecht, an officer of Xeris Biopharma, filed a Form 144 notice of…

Xeris Biopharma Holdings, Inc. · 144 filed Nov 2, 2026 at 16:39 ET

At the news

NEUTRALIMPACT 2/10

144 filed Nov 2, 2026 at 16:39 ET

Beth Hecht, an officer of Xeris Biopharma, filed a Form 144 notice of intent to sell 75,000 shares of common stock with an estimated aggregate market value of $803,250. The shares were acquired through vesting of restricted stock units in January 2025, and the proposed sale is scheduled for November 2, 2026. The filing indicates a pre-existing 10b5-1 trading plan, with prior sales under the plan in August, September, and October 2026.

  • Beth Hecht, an officer, filed Form 144 to sell 75,000 shares of XERS common stock.
  • Estimated aggregate market value of the proposed sale is $803,250.
  • Shares were acquired via vesting of restricted stock units between January 3, 2025 and January 31, 2025.
  • The proposed sale date is November 2, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access